MSLT-I was the first and currently only randomized controlled trial to specifically study the accuracy, morbidity, risks and clinical outcomes of SLNB in the treatment of melanoma. To date, there have ...
ASCO has a new guideline update recommending a more limited role for sentinel lymph node biopsy (SLNB) in early-stage breast cancer. According to the recommendation, several types of patients -- ...
SAN ANTONIO — Recent findings from the INSEMA trial provided more evidence that omitting axillary sentinel lymph node biopsy (SLNB) does not compromise survival in women with low-risk, early-stage ...
Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ...
Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity than the Melanoma ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from its prospective ...
Society of Surgical Oncology Choosing Wisely discourages routine SLNB in women ≥70 years with cN0, HR-positive/HER2-negative invasive disease, supported by CALGB ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company applying innovative diagnostics to inform disease management and improve patient outcomes, today announced the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results